Eris sees a sweet spot as it forays into insulin market, eyes 10% share

Ahmedabad-based chronic therapy-focused drug firm Eris Lifesciences (Eris) is foraying into an oligopolistic insulin market with its own insulin brand this month. The insulin market in India is dominated by multinationals like Sanofi and Novo Nordisk.

The Indian pharmaceutical market (IPM) for insulin is worth Rs 3,500 crore. It has grown at a 10 per cent compound annual growth rate (CAGR) over the past five years. The leading players in this segment are Novo Nordisk (through a distribution arrangement with Abbott India) with 50 per cent share of the market, Sanofi (22 per cent), Lupin (11 per cent), and Biocon (7.5